Madrigal Pharmaceuticals, Inc.MDGLNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank86
3Y CAGR+48.4%
5Y CAGR-16.2%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+48.4%/yr
vs +48.0%/yr prior
5Y CAGR
-16.2%/yr
Recent acceleration
Acceleration
+0.4pp
Accelerating
Percentile
P86
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 64.13% |
| 2024 | -13.08% |
| 2023 | 10.96% |
| 2022 | 19.63% |
| 2021 | 11.01% |
| 2020 | 155.53% |
| 2019 | 184.86% |
| 2018 | 4.10% |
| 2017 | 53.07% |
| 2016 | -70.61% |